Yesterday, Jan. 19, 2016, 43 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $14,412,227.38.

Highlighted Stocks Traded by Insiders:

Pinnacle Entertainment (PNK) - FREE Research Report

Godfrey John A, who is EVP, Sec. & GC at Pinnacle Entertainment, sold 1,000 shares at $7.22 on Jan. 19, 2016. Following this transaction, the EVP, Sec. & GC owned 200,858 shares meaning that the stake was reduced by 0.5% with the 1,000-share transaction.

The shares most recently traded at $32.79, up $25.57, or 77.98% since the insider transaction. Historical insider transactions for Pinnacle Entertainment go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 10,000

The average volume for Pinnacle Entertainment has been 513,600 shares per day over the past 30 days. Pinnacle Entertainment has a market cap of $2.1 billion and is part of the services sector and leisure industry. Shares are up 51.01% year-to-date as of the close of trading on Friday.

Pinnacle Entertainment, Inc. owns, develops, and operates casinos and related hospitality and entertainment facilities in the United States. Its Midwest segment operates Ameristar Council Bluffs, Ameristar East Chicago, Ameristar Kansas City, Ameristar St. The company has a P/E ratio of 29.2.

Exclusive Offer: Get the latest Stock Analysis on PNK - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GameStop (GME) - FREE Research Report

Shern Stephanie M, who is Director at GameStop, sold 3,231 shares at $25.47 on Jan. 19, 2016. Following this transaction, the Director owned 11,276 shares meaning that the stake was reduced by 22.27% with the 3,231-share transaction.

The shares most recently traded at $24.57, down $0.90, or 3.68% since the insider transaction. Historical insider transactions for GameStop go as follows:

  • 4-Week # shares sold: 1,250
  • 12-Week # shares sold: 1,250
  • 24-Week # shares sold: 100,262

The average volume for GameStop has been 2.9 million shares per day over the past 30 days. GameStop has a market cap of $2.7 billion and is part of the services sector and retail industry. Shares are down 9.02% year-to-date as of the close of trading on Tuesday.

GameStop Corp. operates as a multichannel video game retailer. The stock currently has a dividend yield of 5.62%. The company has a P/E ratio of 7.1. Currently, there are 6 analysts who rate GameStop a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GME - FREE

TheStreet Quant Ratings

rates GameStop as a

hold

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, a generally disappointing performance in the stock itself and unimpressive growth in net income. Get the full

GameStop Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Zane Lee, who is SVP and Chief Medical Officer at Anacor Pharmaceuticals, sold 1,466 shares at $89.57 on Jan. 19, 2016. Following this transaction, the SVP and Chief Medical Officer owned 27,281 shares meaning that the stake was reduced by 5.1% with the 1,466-share transaction.

The shares most recently traded at $89.25, down $0.32, or 0.36% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,121
  • 12-Week # shares sold: 44,121
  • 24-Week # shares sold: 44,121

The average volume for Anacor Pharmaceuticals has been 771,000 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are down 19.68% year-to-date as of the close of trading on Tuesday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings

rates Anacor Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full

Anacor Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.